MAM
Publicis.Sapient boosts digital business transformation capability with exec hires
MUMBAI: Publicis.Sapient, the digital business transformation hub of Publicis Groupe, has recently appointed two new executives from the global retail and technology giants Tesco and Amazon as it grows its capability to help clients build businesses of the future.
Tilak Doddapaneni will take the position of global head of engineering at Publicis.Sapient. Prior to this, Doddapaneni was online engineering director at Tesco. In his new role, he will report to Publicis Groupe lead digitalbusiness transformation and CEO Nigel Vaz.
Rakesh Ravuri, who has held a succession of senior engineering roles at Amazon, will join as chief technology officer for programming languages and cloud and global head of engineering for retail. He will play a key leadership role in Publicis.Sapient’s extensive operations in India. Ravuri will report to Doddapaneni. Both Doddapaneni and Ravuri are Sapient alumni.
Publicis.Sapient EMEA and APAC CEO Nigel Vaz said, “I’m delighted that Tilak and Rakesh will be joining Publicis.Sapient on our journey to build our engineering capability as part of our product engineering approach to deliver digital business transformation for our clients. Tilak has exceptional pedigree as a senior leader driving transformational change for one of the world’s biggest retailers through an appreciation of the power that technology and engineering have, as well as an understanding of how to apply that in the evolution of product and experience.”
“His wealth of experience makes him the right person to lead the implementation of our agile engineering model globally. Rakesh comes to us having recently successfully led the engineering team that developed Amazon delivery, one of the most significant revenue generating businesses for a global technology and retail leader,” he added.
Commenting on his new role Doddapaneni said, “As someone who is passionate about engineering and running large software systems, I am excited to return to Sapient, which continues to lead the way as a digital transformation company that uniquely combines strategy, experience and engineering disciplines to help clients reimagine and transform their businesses for a digital age. Building a company that has, develops and attracts world-class engineering talent is what has brought me back to Sapient.”
Pubilics.Sapient chief technology officer Rakesh Ravuri said, “The industry is at an inflection point and technology has moved from support role to the driver’s seat. Sapient is right at the centre of this, with its focus on digital business transformation. I am excited to have a chance to play a leading role in the engineering transformation both for Sapient and its clients.”
Doddapaneni will lead the entire technology delivery community across Publicis.Sapient globally. In addition to client success and engineering and delivery excellence, he will focus on the talent development, performance metrics, and breakthrough engineering practices required by digital business transformation clients in their modern test and learn environments.
Ravuri brings a wealth of knowledge in cloud platforms, service design and agile engineering gained as director of software development at Amazon.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
